₹-15.45
(Market cap
₹461 Cr
Recently Viewed
Clear AllMarket cap
₹461 Cr
Revenue (TTM)
₹165 Cr
P/E Ratio
14.2
P/B Ratio
2.4
Div. Yield
1.7 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹32 Cr
ROE
20.2 %
ROCE
27.9 %
Industry P/E
48.2
EV/EBITDA
9.4
Debt to Equity
0
Book Value
₹427.8
EPS
₹73.5
Face value
10
Shares outstanding
4,413,300
CFO
₹143.76 Cr
EBITDA
₹255.61 Cr
Net Profit
₹197.61 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jenburkt Pharma
| -4.2 | 9.0 | 1.9 | -4.1 | 14.2 | 18.4 | 8.1 |
|
BSE Healthcare
| 0.4 | 5.5 | 5.6 | 2.2 | 24.1 | 13.3 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Jenburkt Pharma
| -10.7 | 79.0 | 4.6 | 22.0 | 26.0 | 8.7 | -30.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Jenburkt Pharma
|
1,044.6 | 461.0 | 165.2 | 32.4 | 22.6 | 18.3 | 14.2 | 2.4 |
| 2,395.0 | 19,609.0 | 1,215.1 | 284.8 | 28.7 | 21.1 | 68.3 | 12.9 | |
| 751.1 | 14,763.9 | 7,266.8 | 627.5 | 11.9 | 12.6 | 23.5 | 2.7 | |
| 689.5 | 17,075.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 31.3 | 3.9 | |
| 945.4 | 15,043.3 | 7,918.4 | 429.9 | 10.7 | 7.2 | 34.8 | 2.3 | |
| 1,093.2 | 19,566.9 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,824.3 | 20,796.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1034.6 | 3.6 | |
| 165.5 | 21,992.4 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.8 | |
| 421.2 | 16,971.8 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48.2 | 3.6 | |
| 1,405.2 | 22,831.0 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1037.8 | 4.9 |
No Review & Analysis are available.
Jenburkt Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical formulations primarily in India. It offers products in various therapeutic areas, such as pain management, neuropathic pain, anthelmintics, analgesics and... antipyretics, anti-arthritic, anti-diabetic, anti-infective, anti-fungal, anti-malarial, anti-ulcerant/antacid, aphrodisiac, cough and cold, and muscle relaxants, as well as nutraceutical and consumer products. The company provides its products through stockists and super stockists to doctors, chemists, large government and semi-government institutions, missionary hospitals, public sector enterprises, etc. It also exports its products to approximately 13 countries. The company was founded in 1985 and is based in Mumbai, India. Read more
Incorporated
1985
Chairman
Ashish U Bhuta
Managing Director
Ashish U Bhuta
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Jenburkt Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Jenburkt Pharmaceuticals Ltd is ₹1,044.55 (BSE) as of 24-Apr-2026 IST. Jenburkt Pharmaceuticals Ltd has given a return of 14.24% in the last 3 years.
The P/E ratio of Jenburkt Pharmaceuticals Ltd is 14.22 times as on 24-Apr-2026, a 70 discount to its peers’ median range of 48.20 times.
The P/B ratio of Jenburkt Pharmaceuticals Ltd is 2.44 times as on 24-Apr-2026, a 32 discount to its peers’ median range of 3.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.93
|
2.60
|
|
2024
|
11.71
|
2.10
|
|
2023
|
11.94
|
2.40
|
|
2022
|
11.66
|
2.22
|
|
2021
|
11.08
|
1.86
|
The 52-week high and low of Jenburkt Pharmaceuticals Ltd are Rs 1,410.00 and Rs 944.00 as of 26-Apr-2026.
Jenburkt Pharmaceuticals Ltd has a market capitalisation of ₹ 461 Cr as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Jenburkt Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.